CA3224904A1 — Sirna inhibiting angptl3 gene expression and use thereof
Assigned to Shanghai Junshi Biosciences Co Ltd · Expires 2022-12-29 · 3y expired
What this patent protects
The present invention relates to siRNA inhibiting angiogenin-like protein 3 (ANGPTL3) gene expression, an siRNA conjugate and a pharmaceutical composition thereof, and a method of reducing ANGPTL3 gene expression by using the siRNA, and the siRNA conjugate and the pharmaceutical …
USPTO Abstract
The present invention relates to siRNA inhibiting angiogenin-like protein 3 (ANGPTL3) gene expression, an siRNA conjugate and a pharmaceutical composition thereof, and a method of reducing ANGPTL3 gene expression by using the siRNA, and the siRNA conjugate and the pharmaceutical composition thereof. The siRNA, and the siRNA conjugate and the pharmaceutical composition thereof can be used for treating and/or preventing ANGPTL3 gene-mediated diseases or disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.